^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SHR-A2009
i
Other names: SHR-A2009, SHRA2009, SHR A2009
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Jiangsu Hengrui Pharma
Drug class:
Topoisomerase I inhibitor, HER3-targeted antibody-drug conjugate
Related drugs:
23d
Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer (clinicaltrials.gov)
P1/2, N=350, Recruiting, Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
trastuzumab rezetecan (SHR-A1811) • Ariely (adebrelimab) • SHR-A2009
1m
A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC (clinicaltrials.gov)
P3, N=500, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
New P3 trial • Metastases
|
cisplatin • carboplatin • SHR-A2009
2ms
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer (clinicaltrials.gov)
P2, N=120, Recruiting, Fudan University
New P2 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
HER-2 expression
|
trastuzumab rezetecan (SHR-A1811) • SHR-A2102 • SHR-A2009 • tizetatug rezetecan (SHR-A1921)
3ms
BCTOP-L-M05: SNF Platform Study of HR+/ HER2-advanced Breast Cancer (clinicaltrials.gov)
P2, N=620, Recruiting, Fudan University | N=140 --> 620
Enrollment change
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HER-2 amplification • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
|
Avastin (bevacizumab) • sorafenib • everolimus • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine • albumin-bound paclitaxel • fulvestrant • exemestane • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • SHR-A2102 • SHR-A2009 • tizetatug rezetecan (SHR-A1921)
3ms
CAP 02: A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
P2, N=147, Recruiting, The First Affiliated Hospital of Zhengzhou University | Trial completion date: Dec 2024 --> Dec 2025
Trial completion date • Metastases
|
AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Ariely (adebrelimab) • SHR-A2009
6ms
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=156, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
New P1/2 trial • Combination therapy • Metastases
|
carboplatin • pemetrexed • Ameile (aumolertinib) • SHR-A2009 • tizetatug rezetecan (SHR-A1921)
6ms
Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC (clinicaltrials.gov)
P2, N=30, Not yet recruiting, Henan Cancer Hospital
New P2 trial • Metastases
|
SHR-A2009 • tizetatug rezetecan (SHR-A1921)
11ms
Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer (clinicaltrials.gov)
P1/2, N=350, Not yet recruiting, Shandong Suncadia Medicine Co., Ltd.
New P1/2 trial • Metastases
|
trastuzumab rezetecan (SHR-A1811) • Ariely (adebrelimab) • SHR-A2009
1year
A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=270, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
New P1/2 trial • Combination therapy • Metastases
|
Ameile (aumolertinib) • Ariely (adebrelimab) • SHR-A2009
1year
The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=19, Active, not recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting --> Active, not recruiting | N=172 --> 19
Enrollment closed • Enrollment change • Metastases
|
SHR-A2009
over1year
Phase I study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumors (ESMO 2023)
Conclusions SHR-A2009 showed a tolerable safety profile and encouraging anti-tumor activity in pts with heavily pretreated advanced solid tumors. The trial is ongoing to assess SHR-A2009 at higher doses and in selected cancer types (NSCLC and other solid tumors).
P1 data • Metastases
|
ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
|
EGFR mutation • ERBB3 expression
|
SHR-A2009
Share via
